Fed. Circ. Upholds Invalidity Of Purdue's Sleep Aid Patents
IP Law 360 published an article on January 11, 2016 about the Federal Circuit's ruling on January 8, 2016 to uphold a New Jersey district court’s ruling in favor of Actavis Elizabeth LLC and other drugmakers finding that three of Purdue Pharmaceutical Products LP’s patents for the sleep aid Intermezzo are invalid because they were obvious.
Jeffery B. Arnold, a litigator with Cantor Colburn who represents Dr. Reddy's, was quoted in the article: "We maintained from the beginning that the claimed inventions were obvious and worked hard to successfully demonstrate this at trial. We are gratified that the Federal Circuit agreed and promptly upheld the District Court’s findings."
Cantor Colburn has strong Pharmaceutical Litigation and Pharmaceutical Patents Practice Groups. The attorneys in this Pharmaceutical Litigation Practice Group focus on defending the rights of both drug discovery companies seeking to protect and enforce their patent rights, as well as defending generic pharmaceutical companies against allegations of patent infringement, including actions arising out of ANDA filings. The attorneys and agent in the Pharmaceutical Patents Practice Group offer a full range of patent application preparation and prosecution services. Many of the professionals in this practice have advanced degrees in chemistry and the life sciences. They have drafted and prosecuted applications for small molecule pharmaceuticals, biopharmaceuticals, bioinformatics, personalized medicine, polymorphs, pharmaceutical formulations, methods of treatment, methods of manufacture, and diagnostic methods.